Nefazodone updated on 07-01-2025

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S11770
R43251		 Anderson, 2020 Major birth defects 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.37 [0.08;1.86] C 3/6   30,627/42,102 30,630 6
ref
S11751
R43195		 Einarson, 2009 Major malformations 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 0.75 [0.10;5.67] C 1/49   25/928 26 49
ref
Total 2 studies 0.49 [0.14;1.72] 30,656 55
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 0.37[0.08; 1.86]30,630661%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Einarson, 2009Einarson, 2009 0.75[0.10; 5.67]264939%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 0% 0.49[0.14; 1.72]30,656550.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.75[0.10; 5.67]2649 -NAEinarson, 2009 1 case control studiescase control studies 0.37[0.08; 1.86]30,6306 -NAAnderson, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.49[0.14; 1.72]30,656550%NAAnderson, 2020 Einarson, 2009 2 Tags Adjustment   - No  - No 0.49[0.14; 1.72]30,656550%NAAnderson, 2020 Einarson, 2009 2 Monotherapy   - no or not specified  - no or not specified 0.75[0.10; 5.67]2649 -NAEinarson, 2009 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.37[0.08; 1.86]30,6306 -NAAnderson, 2020 1 All studiesAll studies 0.49[0.14; 1.72]30,656550%NAAnderson, 2020 Einarson, 2009 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.49[0.14; 1.72]30,656550%NAAnderson, 2020 Einarson, 2009 20.510.01.0